Several papers presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin will describe new developments on the topic.
A highlighted session on the congress’s last day explores recent development in progressive MS. While much of the research on using Nf-L as a biomarker focuses on relapsing remitting MS, researchers from University Hospital, Basel, Switzerland, and Novartis used data from placebo-controlled, phase 3 trials of fingolimod () and siponimod ( ) to learn how to use biomarkers to track brain atrophy in patients with primary and secondary progressive MS. Hear the from lead researcher , in Hall A at 10:30 a.m. (local time) on Friday, Oct. 12.
Nf-L also is being looked at as a way to suss out treatment failure. Researchers with the Swiss MS Cohort Study will present their study of Nf-L as a biomarker of suboptimal treatment response in patients with relapsing remitting MS on established disease-modifying therapy. Theirwill be presented by Özguer Yaldizli, MD, also of University Hospital, also in Hall A, at 8:30 a.m. (local time) on Friday, Oct. 12.
Follow #ECTRIMS2018 on Twitter to see live highlights and perspective from researchers and meeting attendees.